Salarius Historical Cash Flow

SLRX Stock

USD 1.43 0.02 1.38%

Analysis of Salarius Pharmaceuticals cash flow over time is an excellent tool to project Salarius Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 6.3 K or Depreciation of 9.5 K as it is a great indicator of Salarius Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Salarius Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Salarius Pharmaceuticals is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

About Salarius Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Salarius balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Salarius's non-liquid assets can be easily converted into cash.

Salarius Pharmaceuticals Cash Flow Chart

Salarius Pharmaceuticals reported Investments of (1.5 Million) in 2023. Begin Period Cash Flow is likely to rise to about 18.2 M in 2024, whereas Sale Purchase Of Stock is likely to drop slightly above 12.6 M in 2024.

Stock Based Compensation Total Cashflows From Investing Activities Other Non Cash Items Cash Flows Other Operating End Period Cash Flow Other Cashflows From Investing Activities

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Total Cashflows From Investing Activities

The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.

Most accounts from Salarius Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Salarius Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.Salarius Pharmaceuticals reported Investments of (1.5 Million) in 2023. Begin Period Cash Flow is likely to rise to about 18.2 M in 2024, whereas Sale Purchase Of Stock is likely to drop slightly above 12.6 M in 2024.

Salarius Pharmaceuticals cash flow statement Correlations

	Sale Purchase Of Stock	Investments	Change In Cash	Stock Based Compensation	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Net Income	End Period Cash Flow	Change To Netincome	Change To Liabilities	Change To Inventory	Net Borrowings	Change To Account Receivables	Change To Operating Activities	Issuance Of Capital Stock	Change Receivables
Sale Purchase Of Stock		-0.91	0.87	0.74	-0.12	0.57	0.35	-0.47	-0.1	0.07	0.99	0.4	-0.38	0.96	0.33	0.64	-0.22	0.19	-0.11	-0.45	-0.34	0.4
Investments	-0.91		-0.66	-0.73	0.14	-0.49	-0.53	0.48	0.09	-0.17	-0.91	-0.38	0.37	-0.88	-0.32	-0.58	0.25	-0.18	0.08	0.51	0.29	-0.35
Change In Cash	0.87	-0.66		0.48	0.2	0.38	-0.1	-0.5	-0.28	-0.25	0.87	0.4	-0.02	0.82	0.14	0.35	-0.17	0.05	-0.14	-0.39	-0.05	0.29
Stock Based Compensation	0.74	-0.73	0.48		-0.7	0.58	0.78	0.19	-0.24	0.12	0.7	-0.2	-0.78	0.87	-0.04	0.68	-0.31	0.41	-0.17	-0.56	-0.65	0.79
Free Cash Flow	-0.12	0.14	0.2	-0.7		-0.38	-0.83	-0.71	-0.04	-0.33	-0.06	0.59	0.91	-0.31	0.2	-0.57	0.21	-0.44	0.06	0.15	0.72	-0.68
Change In Working Capital	0.57	-0.49	0.38	0.58	-0.38		0.53	-0.13	0.31	0.46	0.55	0.31	-0.69	0.64	0.3	0.36	-0.54	0.37	0.34	-0.58	-0.15	0.12
Begin Period Cash Flow	0.35	-0.53	-0.1	0.78	-0.83	0.53		0.32	0.1	0.46	0.31	-0.25	-0.87	0.49	0.04	0.59	-0.35	0.43	0.06	-0.37	-0.58	0.52
Depreciation	-0.47	0.48	-0.5	0.19	-0.71	-0.13	0.32		-0.23	-0.09	-0.53	-0.92	-0.42	-0.24	-0.63	-0.01	-0.03	0.25	-0.14	0.05	-0.37	0.53
Other Non Cash Items	-0.1	0.09	-0.28	-0.24	-0.04	0.31	0.1	-0.23		0.91	-0.1	0.29	-0.27	-0.18	0.4	0.08	0.0	-0.01	0.27	0.21	-0.09	-0.42
Capital Expenditures	0.07	-0.17	-0.25	0.12	-0.33	0.46	0.46	-0.09	0.91		0.06	0.13	-0.55	0.06	0.3	0.24	-0.1	0.12	0.18	-0.06	-0.32	-0.12
Cash And Cash Equivalents Changes	0.99	-0.91	0.87	0.7	-0.06	0.55	0.31	-0.53	-0.1	0.06		0.46	-0.33	0.93	0.39	0.61	-0.21	0.18	-0.08	-0.45	-0.3	0.35
Cash Flows Other Operating	0.4	-0.38	0.4	-0.2	0.59	0.31	-0.25	-0.92	0.29	0.13	0.46		0.29	0.19	0.68	0.0	0.06	-0.33	0.16	0.0	0.45	-0.67
Net Income	-0.38	0.37	-0.02	-0.78	0.91	-0.69	-0.87	-0.42	-0.27	-0.55	-0.33	0.29		-0.53	-0.02	-0.64	0.34	-0.47	-0.06	0.32	0.68	-0.57
End Period Cash Flow	0.96	-0.88	0.82	0.87	-0.31	0.64	0.49	-0.24	-0.18	0.06	0.93	0.19	-0.53		0.11	0.64	-0.35	0.29	-0.11	-0.55	-0.38	0.56
Change To Netincome	0.33	-0.32	0.14	-0.04	0.2	0.3	0.04	-0.63	0.4	0.3	0.39	0.68	-0.02	0.11		0.33	-0.14	0.24	0.49	0.03	-0.13	-0.34
Change To Liabilities	0.64	-0.58	0.35	0.68	-0.57	0.36	0.59	-0.01	0.08	0.24	0.61	0.0	-0.64	0.64	0.33		-0.28	0.48	0.09	0.11	-0.67	0.52
Change To Inventory	-0.22	0.25	-0.17	-0.31	0.21	-0.54	-0.35	-0.03	0.0	-0.1	-0.21	0.06	0.34	-0.35	-0.14	-0.28		-0.85	-0.81	0.42	0.01	-0.25
Net Borrowings	0.19	-0.18	0.05	0.41	-0.44	0.37	0.43	0.25	-0.01	0.12	0.18	-0.33	-0.47	0.29	0.24	0.48	-0.85		0.72	-0.3	-0.47	0.52
Change To Account Receivables	-0.11	0.08	-0.14	-0.17	0.06	0.34	0.06	-0.14	0.27	0.18	-0.08	0.16	-0.06	-0.11	0.49	0.09	-0.81	0.72		-0.08	0.15	-0.21
Change To Operating Activities	-0.45	0.51	-0.39	-0.56	0.15	-0.58	-0.37	0.05	0.21	-0.06	-0.45	0.0	0.32	-0.55	0.03	0.11	0.42	-0.3	-0.08		0.11	-0.36
Issuance Of Capital Stock	-0.34	0.29	-0.05	-0.65	0.72	-0.15	-0.58	-0.37	-0.09	-0.32	-0.3	0.45	0.68	-0.38	-0.13	-0.67	0.01	-0.47	0.15	0.11		-0.75
Change Receivables	0.4	-0.35	0.29	0.79	-0.68	0.12	0.52	0.53	-0.42	-0.12	0.35	-0.67	-0.57	0.56	-0.34	0.52	-0.25	0.52	-0.21	-0.36	-0.75

Click cells to compare fundamentals

Salarius Pharmaceuticals Account Relationship Matchups

Salarius Pharmaceuticals cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Sale Purchase Of Stock	2.6K	(615.0K)	(3.7M)	18.7M	16.8M	12.6M
Investments	24.5M	14.1M	5.6M	(2.6K)	(1.5M)	0.0
Change In Cash	(2.4M)	7.4M	18.1M	(17.1M)	(6.2M)	(5.9M)
Stock Based Compensation	751.6K	319.4K	559.0K	796.8K	524.8K	498.6K
Free Cash Flow	(11.6M)	(10.3M)	(10.2M)	(19.1M)	(12.8M)	(13.5M)
Change In Working Capital	(4.2M)	(3.0M)	2.0M	2.4M	(968.3K)	(919.9K)
Begin Period Cash Flow	6.1M	3.7M	11.1M	29.2M	12.1M	18.2M
Other Cashflows From Financing Activities	3.7M	17.7M	28.3M	(1.5M)	6.6K	6.3K
Depreciation	127.4K	18.1K	19.2K	6.7K	10.1K	9.5K
Other Non Cash Items	(1.3M)	(258.6K)	(44.7K)	10.8M	130K	123.5K
Total Cash From Operating Activities	(11.6M)	(10.3M)	(10.2M)	(17.6M)	(12.8M)	(13.5M)
Net Income	(6.9M)	(7.4M)	(12.8M)	(31.6M)	(12.5M)	(13.2M)
Total Cash From Financing Activities	3.6M	17.7M	28.3M	2.0M	6.6M	12.4M
End Period Cash Flow	3.7M	11.1M	29.2M	12.1M	5.9M	5.6M
Change To Netincome	(559.7K)	60.8K	514.4K	11.6M	13.4M	14.1M
Change To Liabilities	(839.9K)	(544.5K)	(310.7K)	1.3M	1.2M	621.8K
Change To Inventory	1.2K	3.9M	(2.2M)	(1.0)	(1.15)	(1.09)
Change To Account Receivables	690.0	(3.9M)	2.2M	1.5M	1.7M	1.8M
Change To Operating Activities	(229.1K)	1.4M	99.7K	1.1M	1.2M	819.5K
Issuance Of Capital Stock	4.1M	14.8M	27.3M	2.0M	6.9M	10.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Salarius Historical Cash Flow

About Salarius Cash Flow Analysis

Salarius Pharmaceuticals Cash Flow Chart

Stock Based Compensation

Total Cashflows From Investing Activities

Salarius Pharmaceuticals cash flow statement Correlations

Salarius Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Salarius Pharmaceuticals cash flow statement Accounts

Also Currently Popular

Additional Tools for Salarius Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Cash Equivalents Changes	+ 0.99	Sale Purchase Of Stock
End Period Cash Flow	+ 0.96	Sale Purchase Of Stock
End Period Cash Flow	+ 0.93	Cash And Cash Equivalents Changes
Net Income	+ 0.91	Free Cash Flow
Capital Expenditures	+ 0.91	Other Non Cash Items
Change In Cash	+ 0.87	Sale Purchase Of Stock

Cash Flows Other Operating	- 0.92	Depreciation
Cash And Cash Equivalents Changes	- 0.91	Investments
Investments	- 0.91	Sale Purchase Of Stock
End Period Cash Flow	- 0.88	Investments
Net Income	- 0.87	Begin Period Cash Flow
Net Borrowings	- 0.85	Change To Inventory